search
Back to results

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
repaglinide
isophane human insulin
insulin
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • HbA1c between 7.5 % and 13.0% (both inclusive)
  • Fasting C-peptide above or equal to 0.33 nmol/l
  • BMI (Body Mass Index) between 25 and 32 kg/m2 (both inclusive)

Exclusion Criteria:

  • Medical history of treatment with insulin within the last 6 months
  • Impaired renal function, defined as serum creatinine above to 1.7 mg/dl (150 µmol/l)

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Rep + NPH

Premixed insulin/NPH

Arm Description

Outcomes

Primary Outcome Measures

Change in HbA1c

Secondary Outcome Measures

Change in FBG (Fasting Blood Glucose)
Change in body weight

Full Information

First Posted
October 31, 2012
Last Updated
February 17, 2017
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT01720303
Brief Title
Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes
Official Title
A Multi-centre, Open, Randomised, Parallel, Controlled Trial to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime Insulin With Insulin Alone in Type 2 Diabetic Subjects Inadequately Controlled With Sulphonylurea ± Biguanide Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
September 19, 2002 (Actual)
Primary Completion Date
April 10, 2003 (Actual)
Study Completion Date
April 10, 2003 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
159 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Rep + NPH
Arm Type
Experimental
Arm Title
Premixed insulin/NPH
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
repaglinide
Intervention Description
2 mg (tablets) before each main meal
Intervention Type
Drug
Intervention Name(s)
isophane human insulin
Intervention Description
Injection s.c. (under the skin) at bedtime
Intervention Type
Drug
Intervention Name(s)
insulin
Intervention Description
Injection s.c. (under the skin) twice daily
Primary Outcome Measure Information:
Title
Change in HbA1c
Secondary Outcome Measure Information:
Title
Change in FBG (Fasting Blood Glucose)
Title
Change in body weight

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HbA1c between 7.5 % and 13.0% (both inclusive) Fasting C-peptide above or equal to 0.33 nmol/l BMI (Body Mass Index) between 25 and 32 kg/m2 (both inclusive) Exclusion Criteria: Medical history of treatment with insulin within the last 6 months Impaired renal function, defined as serum creatinine above to 1.7 mg/dl (150 µmol/l)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100101
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200040
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200433
Country
China

12. IPD Sharing Statement

Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk

Learn more about this trial

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

We'll reach out to this number within 24 hrs